Kytril (Granisetron)

Granisetron works by selectively blocking serotonin 5‑HT3 receptors on peripheral vagal nerves and in the brain’s chemoreceptor trigger zone. This inhibition stops the transmission of emetic signals, reducing both acute and delayed episodes of nausea and vomiting.

The dose of Kytril is determined by the prescribing clinician based on the type of emetogenic stimulus, patient weight, and institutional protocol. Typical regimens involve a single intravenous dose given before chemotherapy, radiation, or surgery, but exact dosing must follow the healthcare provider’s order.

Safety data for granisetron in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by the treating physician in consultation with the patient.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and the necessary import documentation.

Compared with other 5‑HT3 antagonists such as ondansetron, granisetron has a longer half‑life, which can allow for less frequent dosing in certain treatment protocols. Its efficacy in preventing chemotherapy‑induced nausea is comparable, and it may be preferred when a longer duration of action is desired.

Kytril must be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. The vial should remain in its original packaging until use, and any unused solution should be discarded according to local regulations.

Kytril is supplied as a sterile injectable solution for intravenous use. It is typically given as a slow IV push or diluted in compatible IV fluids and administered shortly before the emetogenic stimulus (chemotherapy, radiation, or surgery) under medical supervision.

The most serious adverse reactions include severe allergic responses such as anaphylaxis, cardiac arrhythmias related to QT‑interval prolongation, and rare cases of serotonin syndrome when combined with other serotonergic agents. Patients should be monitored for signs of these conditions during and after administration.

Kytril is contraindicated in individuals with known hypersensitivity to granisetron or any component of the formulation. Caution is advised for patients with a history of prolonged QT interval, severe cardiac disease, or those taking other QT‑prolonging medications; use should be avoided unless the clinical benefit outweighs the risk.